AbbVie Inc.
Skyrizi (risankizumab)
moderately to severely active Crohn's disease (CD)
Countdown
177days
Catalyst readout · ~ Dec 31, 2026 estimated
What's at stake
A key catalyst for Skyrizi (risankizumab) (moderately to severely active Crohn's disease (CD)) is expected ~ Dec 31, 2026.
Primary source
· SEC 8-K
verified 17h ago
“AbbVie announced it submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for Skyrizi (risankizumab) for subcutaneous (SC) induction in the treatment of adult patients with moderately to severely active Cr”